Table 4.
Prevalence of antibody titres in infliximab-treated patients compared with total CP and CDL cohorts.
| Antibody | % Positive in this cohort (total) | Infliximab responders | Infliximab non-responders | % Positive (CDL cohort) | % Positive (CP uncomplicated) | p-value |
|---|---|---|---|---|---|---|
| (n = 27) | (n = 19) | (n = 8) | (n = 67) | (n = 50) | ||
| pANCA | 63 | 63 | 62.5 | 43 | 55 | 0.22 |
| ASCA IgA | 25.9 | 21.1 | 37.5 | 18 | 16 | 0.56 |
| ASCA IgG | 14.8 | 15.8 | 12.5 | 14 | 6 | 0.35 |
| Anti-OmpC | 59 | 57.9 | 62.5 | 44 | 36 | 0.25 |
| Anti-CBir1 | 51.9 | 47.4 | 62.5 | 53.5 | 28.3 | 0.01 |
ASCA, Anti-Saccharomyces cerevisiae antibodies; CDL, Crohn’s disease-like phenotype; CP, chronic refractory pouchitis; pANCA, perinuclear anti neutrophil cytoplasmic antibodies.
**p < 0.01, Kruskal–Wallis test.